Related Experiment Video
Updated: Jun 4, 2026
10:33
Generation of Alginate Microspheres for Biomedical Applications
Published on: August 12, 2012
Genetically engineered alginate lyase-PEG conjugates exhibit enhanced catalytic function and reduced
John W Lamppa1, Margaret E Ackerman, Jennifer I Lai
1Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire, United States of America.
Plos One
|February 23, 2011
Summary
Site-specific PEGylation of alginate lyase (A1-III) enhances its therapeutic potential for bacterial infections. This modified enzyme shows improved activity, reduced immunoreactivity, and superior biofilm removal, making it a promising biotherapeutic agent.
Area of Science:
- Biochemistry
- Enzyme Engineering
- Bacterial Infections
Background:
- Alginate lyase enzymes are potential treatments for bacterial infections, especially in cystic fibrosis.
- Deimmunizing and enhancing enzyme activity is crucial for therapeutic applications.
Purpose of the Study:
- To develop a site-specific PEGylation strategy for A1-III alginate lyase to improve its therapeutic properties.
- To assess the activity, immunoreactivity, and biofilm removal efficacy of the modified enzyme.
Main Methods:
- Genetic engineering and orthogonal maleimide-thiol coupling for site-specific PEGylation.
- In vitro kinetic studies with model and bacterial alginate substrates.
- In vitro binding assays to compare immunoreactivity against specific and human antibody libraries.
- Biofilm removal assays using Pseudomonas aeruginosa on abiotic surfaces.
Main Results:
- Controlled mono-PEGylation maintained wild-type enzyme activity on a model substrate.
- PEGylated A1-III exhibited enhanced kinetics with bacterial alginate.
- The PEGylated enzyme showed substantially reduced immunoreactivity compared to the wild type.
- >90% removal of Pseudomonas aeruginosa biofilms by the PEGylated variant versus 75% by the wild type.
Conclusions:
- Site-specific mono-PEGylation is an effective strategy to deimmunize and enhance A1-III alginate lyase.
- The modified enzyme demonstrates improved performance for treating bacterial infections and biofilms.
- This approach yields a more potent biotherapeutic agent with practical utility.
